spacer
home > white papers > Using Device Strategy to Drive R&D Productivity - Phillips-Medisize
WHITE PAPERS
logo_Phillips-Mk.jpg

Phillips-Medisize

phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web http://www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB

Using Device Strategy to Drive R&D Productivity

Biopharmaceutical companies face sustained pressure from all sides to develop better products at lower costs, delivering value to patients, payers and shareholders. Healthcare costs are rising globally at an unsustainable level, putting the entire healthcare delivery system under pricing pressure. Biopharmaceutical companies have become popular targets, evidenced by increasing scrutiny on prescription medicine prices, even though spending on medicine accounts for only about ~10% of overall spend.
Using Device Strategy to Drive R&D Productivity
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>


Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement